Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology(TM) platform and portfolio
(NASDAQ:EVAX), Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO has commenced Thomas Schmidt appointed permanent Chief Financial Officer COPENHAGEN, Denmark, July 1, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology(TM) powered vaccines, announces several key […]